Myxoid Liposarcoma
Symptoms, Doctors, Treatments, Advances & More

Myxoid Liposarcoma Overview

Save information for later
Sign Up

Learn About Myxoid Liposarcoma

What is the definition of Myxoid Liposarcoma?
Myxoid liposarcoma is a subtype of liposarcoma, tumors that arise in the body's fat tissue. Other categories of liposarcoma include well-differentiated; dedifferentiated; round cell; and pleomorphic. Round cell and Myxoid liposarcomas are sometimes grouped together into one category known as myxoid/round cell liposarcoma (MRCLS). In adults, liposarcomas are the most common type of soft tissue sarcoma. The cause of liposarcomas is not well-established but trauma has been implicated in some cases. Myxoid liposarcomas generally arise in the lower extremities. Symptoms may vary depending on the location of the tumor but may include swelling; decreased range of motion; numbness; fatigue; abdominal pain; weight loss; nausea; and vomiting. Many patients with liposarcoma have no symptoms until the tumor is large and interferes with neighboring structures.
What are the alternative names for Myxoid Liposarcoma?
  • Myxoid liposarcoma
  • MRCLS
  • Myxoid/round cell liposarcoma
  • Myxoliposarcoma
Who are the top Myxoid Liposarcoma Local Doctors?
Elite in Myxoid Liposarcoma
Dr. Sandra D'angelo
Oncology
Elite in Myxoid Liposarcoma
Dr. Sandra D'angelo
Oncology

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
646-583-3648
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sandra D'angelo is an Oncologist practicing medicine in New York, New York. Dr. D'angelo is rated as an Elite provider by MediFind in the treatment of Myxoid Liposarcoma. She is also highly rated in 33 other conditions, according to our data. Her clinical expertise encompasses Synovial Sarcoma, Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, and Liver Embolization. Dr. D'angelo is currently accepting new patients.

Elite in Myxoid Liposarcoma
Dr. Scott M. Schuetze
Oncology | Internal Medicine
Elite in Myxoid Liposarcoma
Dr. Scott M. Schuetze
Oncology | Internal Medicine

Rogel Cancer Center

1500 E Medical Center Dr, Floor B1 Reception E, 
Ann Arbor, MI 
734-647-8902
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Schuetze is an Oncologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Schuetze is rated as an Elite provider by MediFind in the treatment of Myxoid Liposarcoma. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Angiosarcoma, and Myxoid Liposarcoma.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Myxoid Liposarcoma
Dr. Lee Cranmer
Oncology
Elite in Myxoid Liposarcoma
Dr. Lee Cranmer
Oncology

City Of Hope Comprehensive Cancer Center-Duarte

1500 Duarte Rd, 
Duarte, CA 
888-304-3959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lee Cranmer is an Oncologist practicing medicine in Duarte, California. Dr. Cranmer is rated as an Elite provider by MediFind in the treatment of Myxoid Liposarcoma. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, and Myxoid Liposarcoma.

View All Doctors
What are the latest Myxoid Liposarcoma Clinical Trials?
A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated Liposarcoma
A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated Liposarcoma
Enrollment Status: Recruiting
Publish Date: March 13, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. This study will test different doses of mirdametinib in combination with a fixed dose of palbociclib to find the best safe dose for further testing.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Pilot Study of BTX-A51 in Patients With Metastatic and/or Recurrent Liposarcomas Characterized by MDM2 Amplifications, Myxoid Liposarcoma, and CIC-Rearranged Sarcoma
A Pilot Study of BTX-A51 in Patients With Metastatic and/or Recurrent Liposarcomas Characterized by MDM2 Amplifications, Myxoid Liposarcoma, and CIC-Rearranged Sarcoma
Enrollment Status: Recruiting
Publish Date: October 31, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: This study is testing two different doses of BTX-A51 to determine if it is safe and tolerable in participants with liposarcoma with MDM2 amplification, myxoid liposarcoma, and CIC-rearranged sarcoma. The name of the study drug used in this research study is: -BTX-A51 (a type of kinase inhibitor)

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center